CML Growth, Growth Hormone & Metabolism Journal (Vol. 2, No. 3)

Faculty

Needs Statement

CML – Growth, a CME-accredited educational program, systematically identifies, evaluates, and places into clinical context the most important recent studies into the science and medicine of growth. It provides rapid access for busy specialists to a critical and clinically relevant review of the developments that will have most impact on their day-to-day practice and is designed to provide management options for clinicians to allow them to better diagnose and treat patients with growth disorders.

Each issue of CML – Growth will present carefully constructed leading (review) articles, written by practicing specialists, and intended to equip readers with practical knowledge of the area under discussion. These articles are commissioned to support particular educational themes identified by the Editor-in-Chief, Editorial team, and readers. This issue of CML – Growth presents two such leading articles.

Target Audience

This activity is designed to meet the educational needs of multidisciplinary clinicians and healthcare professionals involved in the care of patients with growth disorders.

Objectives

After reading this issue the reader should be able to discuss:
1. Treatment of severe and less-than-severe IFG-1 deficiency;
2. The effects of IGF-1 treatment;
3. The safety of IFG-1 in treating severe IGF-1 deficiency;
4. Genotypic and phenotypic characteristics of GH receptor deficiency;
5. Genetic defects associated with IFG-1 deficiency;
6. ALS/STAT5B deficiency in relation to GH insensitivity.

Accreditation

CME
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Kentucky College of Medicine and Remedica Medical Education. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Faculty Disclosure

Dr. Woods has served on the speaker's bureau for Tercica Inc.

Dr. Backeljauw has received research support and served on the speaker's bureau for Tercica Inc.

Dr. Chernausek received consultant fees from Tercica, Inc. and has received research support from Nestlé Inc.

For a complete list of Editorial Staff disclosures please download the PDF.

Activity Sponsorship

This activity is jointly sponsored by the University of Kentucky and Remedica Medical Education. Supported by an unrestricted educational grant from Tercica Pharmaceuticals.